中位随访 英语是什么意思 - 英语翻译

• median follow-up
• with a median follow up

在 中文 中使用 中位随访 的示例及其翻译为 英语

中位随访时间为20.47个月。
The median follow-up duration was 20.47 months.

结果中位随访时间为707日。
The median follow-up period was 707 days.

结果中位随访时间为707日。
Results The median follow-up was 707 days.

分析时的中位随访时间为17.7个月。
Median follow-up at the time of analysis was 17.7 months.

该研究是长期的，中位随访时间为8.6年。
The study was long-term, with a median followup of 8.6 years.

中位随访时间为10.1年。
The median follow-up was 10.1 years.

本研究中位随访时间是17.8个月。
The median follow-up was 17.8 months.

中位随访21个月后，所有患者均无复发存活。
At a median follow-up of 21 months, all patients were free of recurrence.

在发表时，尚未达到中位无进展生存期，中位随访时间为6.6个月。
At the time of the publication, the median progression-free survival had not been reached, with a median follow up of 6.6 months.

接受lisocel的患者在中位随访11个月时的总缓解率（ORR）为81.5％，其中45.5％达到了完全缓解。
The overall response rate(ORR) at median follow-up of 11 months in patients receiving liso-cel was 81.5% with 45.5% achieving a complete response.

在发表时，尚未达到中位无进展生存期，中位随访时间为6.6个月。
The median progression-free survival had not been reached, with a median follow up of 6.6 months.

中位随访时间为4个药物剂量，但有3位患者在评估前死亡。
The median follow-up was 4 drug doses, though 3 patients died prior to assessment.

中位随访时间是48.6个月，有28%的病人至少活了5年。
Median follow-up for all patients was 48.6 months, with 28% of patients surviving for at least 5 years.

中位随访时间为23.6年（范围，20天-28年）;
Median follow-up was 23.6 years(range, 20 days- 28 years);

在中位随访6.9年期间，844人发生ESRD，853人死亡。
During median follow-up of 6.9 years, 844 individuals developed ESRD, and 853 died.

截至数据截点为止，中位随访时间为8.3个月，总体缓解率为84%，包括59%的完全缓解率；.
With a median follow-up time of 8.3 months at the data cutoff, the overall response rate was 84 percent, including 59 percent complete response;

中位随访时间为5.2年，2年DFS为88％（I期96％，II期78％，III期91％）。
The median follow-up was 5.2 years, and 2-year DFS was 88%(96% stage I, 78% stage II, 91% stage III).

这些患者的中位年龄为76岁，中位随访时间为11个月。
The median age of these patients was 76 years, and the median follow-up period was 11 months.

所有患者均为EGFR突变阳性，中位随访时间为27.3个月。
All patients were EGFR mutation- positive, and the median follow-up period was 27.3 months.

对照组CI上限无法评估）；中位随访：8.6个月；.
For the control arm, the upper CI limit was not estimable; median follow-up 8.6 months;

首次中期分析时（99个事件），Brigatinib组中位随访时间11.0月，克唑替尼组中位随访时间9.3个月。
At the first interim analysis, the median follow-up was 11 months in the brigatinib group and 9.3 months in the crizotinib group.

研究小组审查了124587例抗逆转录病毒患者的记录，中位随访时间为5.2年。
The team examined records of 124,587 antiretroviral patients, with a median follow-up period of 5.2 years.

中位随访15.6个月，无进展生存期为17.4个月，总生存期未达到。
At a median follow-up of 15.6 months, progression-free survival was 17.4 months and overall survival was not reached.

在中位随访14.9年期间，研究人员共记录了155例卒中事件。
During a median follow-up of 14.9 years, 155 incident stroke events were recorded.

中位随访6个月，29名患者中有27名没有发生疾病进展。
At a median follow-up of 6 months, 27 of the 29 patients have not experienced disease progression.

中位随访1年后，无复发生存率和总生存率分别为91.5%和97.3%。
With a median follow-up of one year, rates of relapse-free survival and overall survival were 91.5% and 97.3%, respectively.

在中位随访13个月后，总体缓解率为24%。
After a median follow-up period of 13 months, the overall response rate was 24 percent.

结果显示，中位随访时间为4.8年，期间共确诊35例乳腺癌。
Average follow up was 4.8 years and 35 new cases of breast cancer were identified.

例随访资料中，38例在中位随访9个月有持续性的弱点（IQR3-12个月）。
Among 45 patients with follow-up data, 38 had persistent weakness at a median follow-up of 9 months(IQR, 3-12 months).

中位随访16年（范围9-20年），已确定182例乳腺癌，其中146例为ER阳性。
At a median follow-up of 16 years(range, 9-20 years), 182 incident breast cancers had been ascertained, and 146 were ER positive.